| Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ... Cell 184 (1), 64-75. e11, 2021 | 1066 | 2021 |
| Rapid whole-genome sequencing of Mycobacterium tuberculosis isolates directly from clinical samples AC Brown, JM Bryant, K Einer-Jensen, J Holdstock, DT Houniet, ... Journal of clinical microbiology 53 (7), 2230-2237, 2015 | 306 | 2015 |
| Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis JM Day, HJ Tutill, A Purohit, MJ Reed Endocrine-related cancer 15 (3), 665-692, 2008 | 165 | 2008 |
| 17β‐hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone‐dependent breast cancer JM Day, PA Foster, HJ Tutill, MFC Parsons, SP Newman, SK Chander, ... International journal of cancer 122 (9), 1931-1940, 2008 | 151 | 2008 |
| Human cytomegalovirus haplotype reconstruction reveals high diversity due to superinfection and evidence of within-host recombination J Cudini, S Roy, CJ Houldcroft, JM Bryant, DP Depledge, H Tutill, P Veys, ... Proceedings of the National Academy of Sciences 116 (12), 5693-5698, 2019 | 145 | 2019 |
| E-ring modified steroids as novel potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 DS Fischer, GM Allan, C Bubert, N Vicker, A Smith, HJ Tutill, A Purohit, ... Journal of medicinal chemistry 48 (18), 5749-5770, 2005 | 120 | 2005 |
| Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 GM Allan, HR Lawrence, J Cornet, C Bubert, DS Fischer, N Vicker, ... Journal of medicinal chemistry 49 (4), 1325-1345, 2006 | 104 | 2006 |
| Whole-genome enrichment and sequencing of Chlamydia trachomatisdirectly from clinical samples MT Christiansen, AC Brown, S Kundu, HJ Tutill, R Williams, JR Brown, ... BMC infectious diseases 14, 1-11, 2014 | 91 | 2014 |
| Novel and potent 17β-hydroxysteroid dehydrogenase type 1 inhibitors HR Lawrence, N Vicker, GM Allan, A Smith, MF Mahon, HJ Tutill, ... Journal of medicinal chemistry 48 (8), 2759-2762, 2005 | 82 | 2005 |
| Islands of linkage in an ocean of pervasive recombination reveals two-speed evolution of human cytomegalovirus genomes F Lassalle, DP Depledge, MB Reeves, AC Brown, MT Christiansen, ... Virus evolution 2 (1), vew017, 2016 | 81 | 2016 |
| Detection of low frequency multi-drug resistance and novel putative maribavir resistance in immunocompromised pediatric patients with cytomegalovirus CJ Houldcroft, JM Bryant, DP Depledge, BK Margetts, J Simmonds, ... Frontiers in Microbiology 7, 1317, 2016 | 79 | 2016 |
| The role of 17β-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells SP Newman, CR Ireson, HJ Tutill, JM Day, MFC Parsons, MP Leese, ... Cancer research 66 (1), 324-330, 2006 | 73 | 2006 |
| Genomic investigations of unexplained acute hepatitis in children S Morfopoulou, S Buddle, OE Torres Montaguth, L Atkinson, ... Nature 617 (7961), 564-573, 2023 | 63 | 2023 |
| The development of steroid sulfatase inhibitors for hormone‐dependent cancer therapy JM Day, A Purohit, HJ Tutill, PA Foster, LWL Woo, BVL Potter, MJ Reed Annals of the New York Academy of Sciences 1155 (1), 80-87, 2009 | 57 | 2009 |
| Novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1: Templates for design GM Allan, N Vicker, HR Lawrence, HJ Tutill, JM Day, M Huchet, ... Bioorganic & medicinal chemistry 16 (8), 4438-4456, 2008 | 56 | 2008 |
| Focused libraries of 16‐substituted estrone derivatives and modified E‐ring steroids: inhibitors of 17ß‐hydroxysteroid dehydrogenase type 1 N Vicker, HR Lawrence, GM Allan, C Bubert, A Smith, HJ Tutill, A Purohit, ... ChemMedChem: Chemistry Enabling Drug Discovery 1 (4), 464-481, 2006 | 52 | 2006 |
| The regulation and inhibition of 17β-hydroxysteroid dehydrogenase in breast cancer A Purohit, HJ Tutill, JM Day, SK Chander, HR Lawrence, GM Allan, ... Molecular and cellular endocrinology 248 (1-2), 199-203, 2006 | 48 | 2006 |
| 17β-Hydroxysteroid dehydrogenase Type 1 and Type 2: Association between mRNA expression and activity in cell lines JM Day, HJ Tutill, SP Newman, A Purohit, HR Lawrence, N Vicker, ... Molecular and cellular endocrinology 248 (1-2), 246-249, 2006 | 47 | 2006 |
| Novel, potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 GM Allan, C Bubert, N Vicker, A Smith, HJ Tutill, A Purohit, MJ Reed, ... Molecular and cellular endocrinology 248 (1-2), 204-207, 2006 | 45 | 2006 |
| Low Prevalence of Conjunctival Infection with Chlamydia trachomatis in a Treatment-Naïve Trachoma-Endemic Region of the Solomon Islands RMR Butcher, O Sokana, K Jack, CK Macleod, ME Marks, E Kalae, L Sui, ... PLoS neglected tropical diseases 10 (9), e0004863, 2016 | 44* | 2016 |
Simon P NewmanImperial College LondonVerified email at targetovarian.org.uk
